

2018-08-22

Protocol for the ROSE sustainment (ROSES) study, a sequential multiple assignment randomized trial to determine the minimum necessary intervention to maintain a postpartum depression prevention program in prenatal clinics serving low-income women


Jennifer E. Johnson
Michigan State University

Shannon Wiltsey-Stirman
Stanford University

Alla Sikorskii
Michigan State University

See next page for additional authors

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>

 Part of the [Community Health and Preventive Medicine Commons](#), [Female Urogenital Diseases and Pregnancy Complications Commons](#), [Maternal and Child Health Commons](#), [Mental Disorders Commons](#), [Obstetrics and Gynecology Commons](#), and the [Women's Health Commons](#)

Repository Citation

Johnson, Jennifer E.; Wiltsey-Stirman, Shannon; Sikorskii, Alla; Miller, Ted; King, Amanda; Blume, Jennifer L.; Pham, Xuan; Moore Simas, Tiffany A.; Poleshuck, Ellen; Weinberg, Rebecca; and Zlotnick, Caron, "Protocol for the ROSE sustainment (ROSES) study, a sequential multiple assignment randomized trial to determine the minimum necessary intervention to maintain a postpartum depression prevention program in prenatal clinics serving low-income women" (2018). *Open Access Articles*. 3571.
<https://escholarship.umassmed.edu/oapubs/3571>

Protocol for the ROSE sustainment (ROSES) study, a sequential multiple assignment randomized trial to determine the minimum necessary intervention to maintain a postpartum depression prevention program in prenatal clinics serving low-income women

Authors

Jennifer E. Johnson, Shannon Wiltsey-Stirman, Alla Sikorskii, Ted Miller, Amanda King, Jennifer L. Blume, Xuan Pham, Tiffany A. Moore Simas, Ellen Poleshuck, Rebecca Weinberg, and Caron Zlotnick

Keywords

Cost-effectiveness, Implementation, Postpartum depression, Prenatal care, Prevention, Public assistance, Sustainment

Creative Commons License



This work is licensed under a [Creative Commons Attribution 4.0 License](http://creativecommons.org/licenses/by/4.0/).

Rights and Permissions

© The Author(s). 2018 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

STUDY PROTOCOL

Open Access



Protocol for the ROSE sustainment (ROSES) study, a sequential multiple assignment randomized trial to determine the minimum necessary intervention to maintain a postpartum depression prevention program in prenatal clinics serving low-income women

Jennifer E. Johnson^{1*} , Shannon Wiltsey-Stirman², Alla Sikorskii³, Ted Miller⁴, Amanda King⁵, Jennifer L. Blume⁶, Xuan Pham⁷, Tiffany A. Moore Simas⁸, Ellen Poleshuck⁹, Rebecca Weinberg¹⁰ and Caron Zlotnick^{11,12}

Abstract

Background: More research on sustainment of interventions is needed, especially return on investment (ROI) studies to determine cost-benefit trade-offs for effort required to sustain and how much is gained when effective programs are sustained. The ROSE sustainment (ROSES) study uses a sequential multiple assignment randomized (SMART) design to evaluate the effectiveness and cost-effectiveness of a stepwise approach to sustainment of the ROSE postpartum depression prevention program in 90 outpatient clinics providing prenatal care to pregnant women on public assistance. Postpartum depression (PPD) is common and can have lasting consequences. Outpatient clinics offering prenatal care are an opportune place to provide PPD prevention because most women visit while pregnant. The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is a group educational intervention to prevent PPD, delivered during pregnancy. ROSE has been found to reduce cases of PPD in community prenatal settings serving low-income pregnant women.

Methods: All 90 prenatal clinics will receive enhanced implementation as usual (EIAU; initial training + tools for sustainment). At the first time at which a clinic is determined to be at risk for failure to sustain (i.e., at 3, 6, 9, 12, and 15 months), that clinic will be randomized to receive either (1) no additional implementation support (i.e., EIAU only), or (2) low-intensity coaching and feedback (LICF). If clinics receiving LICF are still at risk at subsequent assessments, they will be randomized to either (1) EIAU + LICF only, or (2) high-intensity coaching and feedback (HICF). Additional follow-up interviews will occur at 18, 24, and 30 months, but no implementation intervention will occur after 18 months. Outcomes include (1) percent sustainment of core program elements at each time point, (2) health impact (PPD rates over time at each clinic) and reach, and (3) ROI (costs and cost-effectiveness) of each sustainment step. Hypothesized mechanisms include sustainment of capacity to deliver core elements and engagement/ownership.

(Continued on next page)

* Correspondence: Jennifer.Johnson@hc.msu.edu

¹Division of Public Health, Michigan State University, 200 East 1st St Room 366, Flint, MI 48502, USA

Full list of author information is available at the end of the article



(Continued from previous page)

Discussion: This study is the first randomized trial evaluating the ROI of a stepped approach to sustainment, a critical unanswered question in implementation science. It will also advance knowledge of implementation mechanisms and clinical care for an at-risk population.

Trial registration: Clinicaltrials.gov, [NCT03267563](https://www.clinicaltrials.gov/ct2/show/study/NCT03267563). Registered June 14, 2018.

Keywords: Implementation, Sustainment, Cost-effectiveness, Postpartum depression, Prevention, Public assistance, Prenatal care

Background

More research on sustainment of interventions is needed. A recent expert consensus report concluded that, “Little is known about how well or under what conditions health innovations are sustained and their gains maintained once they are put into practice” [1]. This report placed high priority on conducting return on investment (ROI) studies to determine how much is gained when effective programs are sustained and cost-benefit trade-offs for effort required to sustain [1]. Limited empirical information on methods and benefits of sustainment can result in (1) discontinuation despite significant investment in initial implementation, or in (2) policymakers being unsure about whether resources should be devoted to implementation and scale-up [1]. The ROSE Sustainment (ROSES) Study evaluates the effectiveness and cost-effectiveness of a stepwise approach to sustainment of an evidence-based postpartum depression prevention program in 90 outpatient prenatal clinics serving women on public assistance.

Clinical context

Postpartum depression (PPD) is a common and impactful public health problem, especially among low-income women. A meta-analysis derived an average prevalence rate of 13% for PPD within the first 12 weeks postpartum [2]. Untreated PPD can have severe and lasting consequences for mother and infant [3–10].

Low-income women have higher rates of PPD (up to 50%) [11–15] than do other income groups [16, 17], are less likely to receive treatment for their PPD [18, 19], and have more severe consequences of untreated PPD on maternal caregiving and child development [7, 20, 21]. Therefore, timely and effective interventions to reduce their PPD risk (i.e., to prevent PPD rather than treat a full blown episode) are critical. However, health professionals have remained focused on identifying and treating perinatal depression after its onset [22, 23], rather than preventing it. Outpatient clinics offering prenatal care are an opportune place to provide PPD prevention because most women visit while pregnant.

The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based practice for reducing cases of PPD among low-income and racially and ethnically diverse women [24]. Designed

to address the high risk of PPD among low-income women, ROSE is administered to pregnant women in small groups, at outpatient clinics providing prenatal care. ROSE teaches interpersonal psychotherapy (IPT)-based skills for improving communication and building social support, identified risk factors for PPD. [2, 25, 26] ROSE is presented as a course to minimize stigma and emphasize the program as an educational experience. ROSE consists of four 90-min group sessions and a post-delivery 50-min individual booster session, with easy to read handouts and homework for each session. Two fully-powered randomized trials [27, 28] and a randomized pilot trial [29] support its effectiveness in reducing cases of PPD among low-income women in the first 3–6 months following childbirth (Table 1).

ROSE is flexible, easy to implement, and can be delivered by individuals already working in prenatal clinics. The ROSE manual is highly scripted. Nurses or medical assistants can deliver ROSE. ROSE overcomes barriers to attendance for low-income women by coordinating sessions with women’s prenatal clinic appointments and having a flexible delivery structure (see Table 2).

Table 1 Randomized trials examining the effectiveness of ROSE in preventing PPD

Population	Sample size	% with PPD: ROSE	% with PPD: usual care	Time post-partum
Pregnant women on public assistance [29]	37	0%*	33%	12 weeks
Women on public assistance at risk for PPD [27] ^a	99	4%*	20%	3 months
Pregnant women on public assistance at PPD risk [28]	205	16%*	31%	6 months
Pregnant adolescents [39]	106	12.5%	25% ^b	6 months
African-American women at risk for PPD [40] ^a	36	Depressive symptoms decreased over time	No change in depressive symptoms	3 months

* $p < .05$ between conditions

^aPer Cooper Survey Questionnaire [76]

^bDose-matched control

sustainment conditions (i.e., low-intensity coaching and feedback [LICF] and high-intensity coaching and feedback [HICF]) will contain lower (every 3 months) and higher (every month) doses of REP's implementation steps (technical assistance, ongoing support of and conversation with the clinics, coaching [including booster training and process evaluation], feedback; Fig. 1). The three implementation interventions provide varying doses of guidance for re-customizing delivery and making organizational and financial changes to sustain the intervention, as suggested in the framework's maintenance and evolution phase.

ROSE Sustainment (ROSES) Study aims

The ROSES Study evaluates cost-effectiveness of a step-wise approach to sustainment of ROSE in 90 outpatient prenatal clinics serving women on public assistance. Specific aims are to

1. Compare effectiveness of each sustainment step for the following final and proximal outcomes:
 - a. Percent sustainment of core program elements at each time point (primary) and total length of time that (i) any ROSE services were provided and (ii) were provided with adequate fidelity to core elements.
 - b. Health impact (e.g., PPD rates over time at each clinic) and reach (number of patients enrolled in and completing the ROSE program).
 - c. Return on investment (costs and cost-effectiveness of each sustainment step)
 - d. Hypothesized mechanisms including sustainment of (i) clinical and organizational capacity to deliver core elements, and (ii) a sense of engagement/ownership by key clinic staff
2. Examine predictors and processes to determine which kinds of clinics need which level of support:
 - a. Explore which clinic characteristics (e.g., organizational and state policy contexts) and hypothesized mechanisms (Aim 1d) are associated with best sustainment to determine tailoring variables for choosing/sequencing EIAU, LICF, and HICF in the future.
 - b. Document implementation/sustainment processes, their timing relative to desired outcomes, and critical incidents to explore factors most related to sustainment after accounting for hypothesized mechanisms.

Innovation

The ROSES Study is innovative in that there are few randomized implementation studies with sustainment as primary outcome. In particular, identifying the "minimum necessarily to sustain" is a novel methodological

[36] aspect of this study. In addition, the ROSES Study is the first implementation study of a PPD prevention intervention in outpatient clinics providing prenatal care. In fact, virtually no interventions that prevent any mental health problem among adults without requiring the use of mental health clinicians have been the subject of implementation research in outpatient medical settings [37].

Finally, dynamic tailoring of implementation interventions is needed to enhance the science of implementation. Clinic and contextual factors lead to heterogeneity in response to implementation interventions. The study's sequential multiple assignment randomized trial (SMART) design, in which we adjust intervention intensity based on risk of failure to sustain, addresses this heterogeneity. Results will build a needed evidence base for precision algorithms for optimizing the allocation of implementation resources to achieve sustainment.

Methods

Preliminary studies

Past work on ROSE

ROSE is effective at reducing PPD cases among low-income women in community settings (see Table 1). Given the highly scripted intervention manual, interventionists with varying qualifications (i.e., paraprofessionals, nurses) have delivered ROSE with fidelity [38]. Delivering ROSE in prenatal clinics is feasible and acceptable to low-income pregnant women, with good session attendance [39, 40] and high perceived helpfulness of intervention components [27]. ROSE is also feasible and acceptable to clinics serving low-income women, as demonstrated by requests for the ROSE manual and/or training across the USA and in Japan, as well as surveys conducted in Michigan (see below).

Pilot work in Michigan

Included staff surveys in 13 prenatal clinics ($n = 27$ respondents). Data suggested that clinics were motivated to implement ROSE. All respondents viewed preventing PPD as "very important" ($n = 24$) or "important" ($n = 3$). All but one respondent was "somewhat" to "very" interested in implementing ROSE for their patients. Data also suggested that clinics had a need for ROSE. As is the case nationally, none of the surveyed clinics had strategies in place to prevent PPD. Instead, most clinics (11/13) tried to provide some regular screening for PPD after birth, indicating that PPD is a priority issue. Data also suggested that implementing ROSE in prenatal clinics is feasible. Ten clinics immediately identified staff that had adequate time and training to lead ROSE groups; three were unsure. EIAU, LICF, and HICF will all work with clinics to identify ROSE group leaders and manage workflow.

When asked what about ROSE might be a good fit for their clinics, respondents described a need (“our patients have significant modifiable risk factors,” “at least half of the pregnant patients are presenting with depression and/or anxiety”), and said that it is better to prevent PPD than to deal with it after it occurs. They also mentioned the non-threatening nature of ROSE (which does not require women to endorse PPD) and the convenience of coming to a familiar office. Implementation facilitators included “We have numerous patients; low income, minority, history of depression,” “nursing staff well aware of the social problems our patients face,” “group setting would increase patients being seen and increase comfort,” and “clients more apt to attend visits.” Using questions based on Steckler [41], respondents agreed that ROSE would be more effective in preventing PPD than current practices and would improve quality of care at their clinics and disagreed that it would be difficult to learn. Motivation of staff to address PPD was viewed as a facilitator.

Clinics were also able to identify supports needed to implement and sustain ROSE, which we integrated into our study implementation conditions. On a scale from “1 = serious barrier” to “7 = strong facilitator,” staff training (4.2), staff time and workload (3.4), billing issues (3.5), and space (3.3) were viewed as neutral to slight barriers, but none was seen as a serious barrier. Informed by these responses, training, time and workload, billing, and space issues are addressed in varying degrees in the three study conditions (EIAU, LICF, and HICF). Respondents rated components of EIAU, LICF, and HICF as important for successful implementation of ROSE at their clinics (see Table 3).

Critical design decisions

Rationale for implementation interventions and a SMART design

The goal of the ROSES study is to determine the minimum intervention needed to sustain ROSE in clinics that provide prenatal services to women on public assistance and the

Table 3 Pilot data: Clinic ratings of need for implementation supports

Ratings of need for implementation supports (1 = least needed, 10 = most needed)	
Supports provided once in EIAU and on an ongoing basis, in higher doses, and in LICF and HICF	Materials for patients about why they might want to participate (9.38) Initial training (8.85) Someone to talk with staff about why the program matters (8.62) Work with office to figure out how to pay for (8.42) Educate staff about PPD/mental health (8.12)
Supports provided only in LICF and HICF:	Audit and feedback (to show that ROSE is working and how; 8.38) Ongoing training (7.50)

optimal timing of boosters. To achieve this goal, the implementation interventions (EIAU, LICF, and HICF) were chosen to reflect different intensities of a standard approach to allow their intensity/cost aspects to take precedence. When an intervention does not produce a desired outcome, two options are available: to give it more time or step up the intervention intensity. The study’s SMART design allows us to isolate the effect of intensifying an intervention (i.e., stepping up to LICF or HICF) versus giving a simpler one (such as EIAU or LICF) more time. It also builds an evidence base for precision algorithms optimizing the allocation of implementation resources to achieve sustainment.

Rationale for sample

We will enroll 90 outpatient medical clinics providing prenatal care in Michigan, Rhode Island, Massachusetts, Pennsylvania, New York, and Florida. We chose to include any kind of outpatient clinic for which ROSE would be appropriate (e.g., federally qualified health centers [FQHCs], hospital-affiliated clinics, independent practices, and visiting nurses) in order to speed knowledge acquisition relevant to widespread scale-up. To be included in the study, clinics will be (1) outpatient, (2) provide prenatal services, (3) estimate that at least 50% of their pregnant patients receive some kind of public assistance (such as federal or state cash assistance, food stamps, subsidized housing, and/or health insurance such as Medicaid), (4) have at least ten new pregnant women per month on average (i.e., enough patient flow to run ROSE), and (5) agree to study procedures. Given the need for prevention of PPD among low-income women, the study addresses ROSE implementation to clinics serving mainly low income women; however, any woman within the clinic can receive ROSE.

Research design

Implementation interventions

Except for one in-person training in HICF, meetings and trainings take place by videoconference or telephone. Trainings and meetings for each clinic will be recorded and provided for optional later viewing.

EIAU consists of initial training and problem-solving plus planning for sustainment and covers the pre-implementation step of the REP framework (Fig. 1). Step 1 study investigators will meet with key clinical and operational staff. This 2-h meeting will include (1) a brief clinical and operational overview of ROSE, (2) problem-solving and discussion around adaptable elements of ROSE, and (3) planning and tools for sustainment. This collaborative process will mesh the clinic’s context, needs (including needs of patient population), and resources, with discussion of ROSE core and adaptable elements, resulting in a written, tailored implementation and sustainment plan that identifies who within the clinic is responsible for what. Step 2 will consist of two

separate video meetings. The first videoconference (60–90 min) will include operational staff to discuss operational issues (such as reimbursement, identification and referral procedures, and identification of suitable providers). The second videoconference will consist of a live 4-h training for providers on how to conduct ROSE. Providers will be given a manual with the ROSE program, patient handouts, a summary of key components, scripts for presenting ROSE to patients, and a customized description of the clinic’s logistics for ROSE. Because training sessions are recorded and there is a written, clinic-specific sustainment plan, it is possible for clinics to replenish staff turnover, but turnover may create risk of not sustaining, which would be addressed in LICF or HICF.

LICF will include EIAU plus low-intensity coaching and feedback, consisting of three components. The first component includes one clinical and one operational telephone “booster” meeting quarterly for additional support (up to 1 h each). Meetings will identify challenges to conducting ROSE with fidelity, collaboratively problem solve solutions, discuss re-customization of delivery if needed, and develop an action plan to address barriers. Subsequent meetings will review implementation progress and collaboratively make changes to the action plan based on new data, experiences, and discussion.

The second component of LICF is provision of feedback to clinical and operational staff during booster meetings to help guide discussion and planning. Clinical feedback will include information about their fidelity to core ROSE elements based on the ROSE session-by-session adherence scale and interview validation (see primary outcome section). We will also provide information to clinical and operational staff on any changes in the clinic’s rates of PPD for the previous quarter and on challenges or successes we detect from survey measures.

Finally, to promote partnership and ownership, clinical and operational staff from clinics assigned to LICF will be invited to participate quarterly in collaborative board phone meetings with study investigators and staff from other study clinics. Staff from LICF clinics will provide feedback to the study team about the implementation strategies being used, helpful adaptations to the intervention that preserve core elements, and ways to address challenges in other clinics.


HICF: Clinics in the HICF condition will receive everything that the clinics in LICF receive, but at a higher intensity. Clinical and operational booster meetings, feedback, and participation in collaborative board meetings will be monthly, rather than quarterly. In the month after randomization to HICF, study investigators will travel to the clinic to provide an in-person clinical and administrative “booster” meeting to increase engagement (a proposed mechanism). The remaining monthly meetings will be by telephone or videoconference. Study investigators will also be available to answer questions on an ad-hoc basis.

Characterizing implementation interventions (EIAU, LICF, HICF)

Every implementation encounter (e.g., initial or ongoing training, collaborative board meetings) will be documented in an electronic implementation case note and audio or video recorded. The case note will include encounter length, time spent on operational vs. clinical support, a checklist of implementation strategies used (taken from Powell et al., 2015) [42], a checklist of discussion topics (e.g., billing options), and free response sections to describe clinic staff responses. We will review and rate 20% of the recordings to verify/augment the notes.

Randomization

After the baseline assessment, all clinics will receive EIAU (initial training + tools for sustainment). Clinics that are determined to be at-risk for operational (defined as no ROSE intervention in 3 months and none planned) and/or clinical (defined as less than 75% fidelity to ROSE core elements) failure to sustain at subsequent assessments up to 15 months will be randomized to receive additional support. At the first time period at which a clinic is determined to be at risk (i.e., at 3, 6, 9, 12, or 15 months), that clinic will be randomized in a 3.8:1 ratio (Fig. 2) to receive either (1) the addition of low-intensity (every 3 months) coaching and feedback (LICF), or (2) no additional implementation support (EIAU only). If clinics receiving LICF are still found to be at risk at subsequent monitoring periods, they will be randomized in a 1:1 ratio to either (1) nothing additional (i.e., EIAU + LICF only), or (2) high-intensity (monthly) coaching and feedback (HICF). Additional study follow-up interviews will occur at 18, 24, and 30 months, but no implementation intervention will



occur after 18 months. Randomization procedures will balance trial arms by time (3, 6, 9, 12, or 15 months) and whether or not the clinic is a FQHC. Figure 2 shows the SMART design.

Statistical power is based on the primary outcome: percent sustainment of core ROSE elements at each time point. We start with powering the comparison created by the second randomization, EIAU+LICF vs. EIAU+LICF+HICF. For this comparison, the literature reports a range of effect sizes, with three out of four most relevant ones [43–45] exceeding Cohen's $d = 0.48$. Aim 1 analyses include adjustment for the 6-month version on the primary outcome (baseline for second randomization) and repeated measures at 9, 12, 15, 18, 24, and 30 months. Assuming correlations between pairs of repeated measures of 0.7 based on past work, $n = 19$ per group is needed to detect the target effect size with power of 0.80 or greater at $\alpha = 0.05$ in two-tailed tests. Assuming that two thirds of the clinics would still be at risk after EIAU + LICF, $n = 38$ clinics will enter into the second randomization. Therefore, one third, or $n = 19$ clinics would be deemed low risk and continue EIAU+LICF. Moving to the left in Fig. 2 to the first randomization, the EIAU + LICF group will have size $n = 57$ as determined above. The size of the other group in the first randomization of $n = 15$ will allow to detect the target effect size with power of 0.89. After the initial EIAU period, we expect approximately 80% of clinics to be at risk [45, 46]. Therefore, 72 ($57 + 15$) clinics in the first randomization will be 80% of the sample. Thus the initial sample size receiving EIAU will be $n = 90$.

Assessments will be conducted at 0, 3, 6, 9, 12, 15, 18, 24, and 30 months. Each clinic will identify two people: the person most involved in ROSE (1) clinical and (2) operational (e.g., billing and scheduling) functions. We anticipate two respondents per clinic, but power and measures are unaffected if they are the same person. Clinic-level measures will be derived from the surveys and analyses occur at the clinic level. Respondents will complete quantitative measures online. Qualitative interviews will take place by phone (see Table 4).

We define operational failure to sustain as no ROSE intervention in 3 months and none planned. We define clinical failure to sustain as less than adequate fidelity to ROSE core elements (i.e., an average of $< 75\%$ of core elements for each session delivered, as measured by the ROSE session-by-session adherence scale; see primary outcome section below). Used in previous ROSE trials (Table 1), this checklist lists on average eight items (rating of present/absent) that assess whether key tasks of each session were completed. Given that ROSE is scripted, item answers are in yes/no format, and core elements are basic (e.g., yes/no—did interventionist explain PPD? Did interventionist have group members

practice communication skills through role plays?); completing 75% of these for “adequate” fidelity is reasonable.

Primary outcome

Our primary outcome reflects the effectiveness of each sustainment step in terms of (a) percent sustainment of core program elements at each time point and (b) total length of time any ROSE services were provided, and length of time they were provided with at least moderate fidelity to core elements. Statistically, one of these measures should be the primary outcome; we have chosen the first because it has repeated measures over time, improving power. ROSE's core program elements (Table 2) will be assessed through the ROSE session-by-session adherence scale, a self-rated intervention fidelity scale completed by ROSE interventionists after each session [28]. The outcome for each time point (i.e., quarter) will be the mean percent of core elements delivered that should have been delivered at each ROSE session (mean [number of core elements delivered/number of core elements should have been delivered] at each session; zero if no sessions were completed). Self-reported checklists of mental health intervention fidelity have shown excellent validity when compared to observer-rated scales [47–50]. We will validate checklist responses against expert ratings using qualitative interviews for three sessions per quarter. Using a monthly calendar method [51, 52], we will track (1) the total length of time any ROSE services were provided, and (2) total amount of time ROSE services were offered with adequate fidelity of core elements (defined as 75% or more on the ROSE session-by-session adherence scale averaged across interventionists and sessions each month).

Secondary outcomes

Health impact (PPD rates over time at each clinic)

Quarterly, we will ask each clinic to report the following overall numbers: (1) number of women who should have come for their 6-week postpartum appointment; (2) number who came; (3) number that were screened for PPD; and (4) number who screened positive for PPD. We will also collect this information for four quarters (12 months) prior to baseline. We will use these numbers to calculate PPD rates for each time period (see below). Although not every woman in the clinic will receive ROSE, we chose to track overall PPD rates at each clinic because: (1) the study examines larger-scale sustainment aimed at clinic-wide (and eventually population-wide) outcomes; and (2) the clinic-level outcomes are primary; not consenting individual patients makes the needed sample size (90 clinics) feasible. Number of patients enrolled in and completing ROSE (i.e., reach) [1]. Clinics will track the

Table 4 ROSES Study schedule of assessments

Assessments	Type	Respondent			Base-line	Follow-ups
		opera-tional	clinical	records*		
Sustainment (primary and secondary outcomes)						
Core elements (delivered/should have been delivered over 3 months)	Session ✓list			X		X
Months ROSE offered, months offered with fidelity	Interview, ✓list		X	X		X
Health impact (# screened, # screened positive for PPD at clinic)	Objective			X	X	X
Reach (# pts. attending ROSE, # completing ROSE)	Objective			X		X
Mechanism: capacity						
Program assessment Sustainability tool: organizational capacity	Survey	X	X		X	X
# trained, trained w/time to deliver, trained and done w/fidelity	Survey, ✓list		X	X		X
Manage space, able to bill for ROSE?	Survey	X			X	X
Mechanism: ownership/engagement						
Program assessment Sustainability tool: four subscales	Survey	X	X		X	X
NHS Sustainability Model and Guide: staff section	Survey	X	X		X	X
Attitudes toward PPD	Survey	X	X		X	X
ROI: costs	Objective			X		X
Predictors and processes						
Implementation climate assessment	Survey	X	X		X	X
State policy context: legislation, maternal mortality rates	Objective				X	X
Dates, process notes from training, and coaching/feedback sessions	Objective			X		X
Other processes and critical incidents	Qualitative	X	X			X
Clinic descriptives	Survey	X			X	X

*Based on records kept by the clinic or the study. The study will not have direct access to individual medical records

number of: (1) patients who agree to come to ROSE, (2) patients attending at least one session, and (3) patients attending at least three of the five sessions. Clinic size (number of new pregnant patients per quarter) and estimated percent of clinic patients on public assistance will be considered in analyses.

Return on investment We will analyze four cost-effectiveness outcome measures: (1) a primary clinical outcome and number of PPD cases averted, estimated as the change in PPD rate at the clinic (post-pre)*(clinic's caseload); (2) another clinical outcome and number of quality-adjusted life years saved, computed from the primary outcome using Morrell et al.'s [24] model; (3) an implementation process outcome and number of clients served with fidelity; and (4) a sustainment outcome and months of additional service delivery. Our grant accounting will capture our costs to provide EIAU, LICF, and HICF. Clinic costs to receive EIAU, LICF, and HICF will be assessed using hours that clinic staff spent on EIAU, LICF, or HICF; associated direct costs (e.g., printing) and staff salaries; and fringe benefits and overheads. In addition to assessing the cost-effectiveness of EIAU, LICF, and HICF, we will also assess the cost-effectiveness of ROSE itself.

We will track ROSE delivery costs at each clinic for one pay period (i.e, 2 weeks) using a time sheet for staff who spend time on ROSE to record their ROSE-related hours, work hours on other programs, residual personal overhead hours, and training time.

Proposed mechanism 1: Clinical and organizational capacity to deliver ROSE The primary measure will be the organizational capacity subscale of the Program Sustainability Assessment Tool [38, 53]. Secondary measures include number of people trained who have time to deliver ROSE and perceiving the clinic as able to manage space/scheduling and to bill/get reimbursed for ROSE.

Proposed mechanism 2: Ownership and engagement by clinic staff Ownership and engagement by clinic staff will be assessed using the sum of other relevant subscales of the Program Sustainability Assessment Tool (primary): communications, partnerships, political support, and strategic planning [38, 53]. The Staff section of the National Health Service's Sustainability Model and Guide [54, 55] and investment in addressing PPD will be secondary measures.

We will assess predictors and processes to provide information about which kinds of sites need which level of

sustainment support. Organizational context will be assessed using Aarons' implementation climate assessment [56, 57]. State policy context will be assessed through two measures: (1) Enacted state legislation about PPD (0 = no state enacted state legislation related to PPD, 1 = awareness-related PPD legislation, 2 = legislation mandating PPD education and services, 3 = legislation with money attached for PPD education/services); and (2) state-level maternal mortality [58, 59].

Processes of implementation and sustainment efforts will be documented using qualitative interviews and implementation case notes. Timing: We will record the dates of EIAU, LICF, and HICF interventions and dates of any change in ROSE status (i.e., ROSE offered, not offered, and ROSE offered with fidelity vs. not) to examine the temporal relationships among these events. Respondent perceptions of critical incidents to sustainment success or failure will be assessed using qualitative interviews.

Analyses

Clinic is the unit of randomization and analysis. Primary analyses will be intent-to-treat. All statistical tests will be two-sided with $\alpha = 0.05$ for sustainment of core program elements (primary) and health impact (secondary) outcomes, specified a priori. In exploratory analyses, false discovery rate due to multiple tests will be controlled using the Hochberg adjustment [60, 61].

Baseline comparisons, regression techniques, and missingness Outcome values at baseline, minimization variables, and clinic characteristics will be compared using t tests, chi-square test, or Fisher's exact test. If systematic differences are found, they will be considered as covariates in further analyses. Since analyses will control for baseline values of outcomes, the extent to which other factors may affect post-randomization outcomes will be reflected in the baseline version. The regression techniques described below allow for missing at random mechanisms [62]. If patterns of missing data indicate not missing at random mechanisms, then models describing missing mechanisms will be considered (e.g., pattern-mixture models) [63, 64], and sensitivity analyses will be employed to investigate the robustness of the results.

Specific Aim 1a, hypothesis 1: Among clinics determined to be at risk after EIAU + LICF, those randomized to receive HICF will have better percent sustainment of core program elements at post-randomization assessments than those randomized to continue EIAU + LICF alone. Hypothesis 2: Among clinics at risk after EIAU, those randomized to EIAU + LICF in the first randomization will have better percent sustainment of core program elements at post-randomization time points than those randomized to continue EIAU alone. Hypotheses will be tested using generalized linear mixed effects (GLME) models with seven

repeated measures for the first randomization and six for the second. Outcome value at 3 months for the first randomization (after the initial EIAU), and at 6 months for the second one (after the initial EIAU+LICF), will be entered as covariates in the respective analyses. Time will be entered as a class variable to model potentially non-linear patterns. The test of the equality of the coefficient for the randomized condition to zero in the GLME model will yield the test for the main (time-averaged) effect of each step-up intervention. To explore any changing intervention effect as time progresses, time by randomized condition interaction will be added to the model. Specific Aim 1b will use an approach similar to Aim 1a.

Specific Aim 1c: We will use an incremental cost-effectiveness analysis, showing cost-effectiveness ratios for EIAU, for adding LICF, and for adding HICF. The cost-effectiveness ratio equals $\Delta C/\Delta E$, where ΔC is the difference in costs as LICF and HICF are added, and ΔE is the difference in the outcome measure. We will bootstrap 95% confidence intervals around the cost-effectiveness ratio and conduct sensitivity analyses.

Specific Aim 1d: Mechanisms of effects of LICF, HICF. Randomized condition will be treated as the independent variable, and hypothesized mechanisms (primary measures of capacity and engagement/ownership) will be treated as potential mediators (one at a time). Effects of mediators on outcomes will be tested by adding them to the GLMEs described above. We will use a bias corrected bootstrapping analytic strategy [65, 66] to estimate confidence intervals around the indirect effect of randomized condition on the outcome, through the mediator. To establish mediation, the 95% confidence interval must not include zero.

Specific Aim 2a explores which kinds of clinics need EIAU, LICF, or HICF and when for optimal sustainment. Characteristics of clinics found to be at risk at each assessment will be compared to those of clinics found to be not at risk using t tests, chi-square test, or Fisher's exact test. Clinic characteristics (size, percent on public assistance, yes/no FQHC), organizational context (implementation climate assessment score), state policy context (rating of state PPD legislation), and hypothesized mechanisms (capacity and engagement/ownership assessed using Program Sustainability Assessment Tool subscale scores) will be considered as potential tailoring variables in defining optimal intervention sequences. The optimal decision rule will be formulated to specify best first and second intervention stage following the initial administration of EIAU. For example, a decision rule might be if a clinic is FQHC, start with LICF and if found to be at risk at 12+ months, step up to HICF, but if found at risk at 6 or 9 months, give LICF more time. The analysis approach follows the optimization method called Q-learning [67–70] with backward induction [71–73].

Specific Aim 2b examines implementation processes, their timing relative to desired outcomes, and critical incidents in order to explore additional factors related to sustainment, as well as dose-response and active ingredients. For quantitative analyses, within each intervention sequence (i.e., EIAU only, EIAU + LICE, and EIAU + LICE + HICE), we will use the GLME technique to relate repeated measures of sustainment outcomes to time and the following time-varying covariates for each time period: intervention dose, count/frequency of specific implementation techniques, ROSE status and occurrence of critical incidents. The same model will be fit for mediators, and then also for outcomes controlling for hypothesized mediators as time-varying covariates.

Qualitative data will include (1) interviews with clinic respondents to capture variation in sustainment and risk and (2) analysis of implementation process notes. Qualitative interviews will occur every 6 months after baseline (at 6, 12, 18, 24, 30 months) with ~ 60 interviews (clinical and operational respondents at 30 clinics) at each time point. At each time point, clinics will be chosen in the following order: (1) any clinic randomized during the time period, (2) any clinic that changed status (from offering ROSE at adequate fidelity to not, or vice versa), and (3) a few clinics that have sustained well. Deductive codes will be drawn from interview question topics and the Critical Incident Technique specified by Pluye [74] to identify critical incidents and processes related to sustainment. Inductive codes capturing emergent themes will arise from team-level review of the transcripts. Codes will be entered into NVivo. Thematic analysis [75] will be used to identify key themes.

Discussion

The ROSE Sustainment Study will be among the first randomized trials evaluating the costs and cost-effectiveness (i.e., ROI) of a stepped approach to sustainment, a critical unanswered question in implementation science. Rigor and reproducibility are ensured by the randomized trial design; clear inclusion criteria for participating clinics; manualized protocols and fidelity assessment for EIAU, LICE, and HICE; careful characterization of implementation processes; reliable and valid measures; and transparent power and statistical analyses. The study's focus on enhancing care of an underserved population, examination of mechanisms and moderators, and ROI analyses increase its relevance. Thus, the study will advance implementation science, knowledge of implementation science mechanisms, and clinical care for at-risk women.

Abbreviations

EIAU: Enhanced implementation as usual; FQHC: Federally qualified health center; GLME: Generalized linear mixed effects; HICE: High-intensity coaching and feedback; IPT: Interpersonal psychotherapy; LICE: Low-intensity coaching and feedback; MDD: Major depressive disorder; PPD: Postpartum depression;

RE-AIM framework: Reach, effectiveness, adoption, implementation, and maintenance together determine public health impact; REP framework: Replicating effective programs; ROI: Return on investment; ROSE program: Reach Out, Stay Strong, Essentials for mothers of newborns; ROSES Study: ROSE Sustainment Study; SMART: Sequential multiple assignment randomized trial

Funding

This study was funded by a grant from the National Institute of Mental Health (NIMH; R01 MH114883, PIs Johnson and Zlotnick; see <http://www.publichealth.msu.edu/flint-research/the-rose-sustainment-study>). NIMH had no role in the design or implementation of the study, analysis of the data, or writing of the manuscript.

Authors' contributions

JJ, CZ, SWS, and AS conceptualized the research project. TM designed the cost-effectiveness analyses. AK, JK, and TP helped to design and collected all the pilot data, including contacting and following up with prenatal clinics. AK also helped with the literature review. TMS, EP, and RW helped to design clinic recruitment procedures for their respective states and are working to engage and retain those clinics. JJ drafted the paper based on the funded NIH grant and all other authors reviewed the manuscript and edited as needed. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The protocol for this study was approved by the Michigan State University Biomedical and Health Institutional Review Board (protocol IP no. 00056524). Consent for participation in the study will be obtained using an electronic informed consent form.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Division of Public Health, Michigan State University, 200 East 1st St Room 366, Flint, MI 48502, USA. ²National Center for PTSD, Dissemination and Training Division and Stanford University Department of Psychiatry and Behavioral Sciences, 795 Willow Road (NC-PTSD 334), Menlo Park, CA 94025, USA. ³Department of Psychiatry, Michigan State University, 909 Fee Rd Room 321, East Lansing, MI 48824, USA. ⁴Pacific Institute for Research and Evaluation, 11720 Beltsville Drive Suite 900, Calverton, MD 20705, USA. ⁵Mayo Clinic, 200 First St, Rochester, MN 55901, USA. ⁶Michigan Medicine, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. ⁷Spectrum Health, 221 Michigan Street, Suite 402 MC 118, Grand Rapids 49503, USA. ⁸University of Massachusetts Medical School/UMass Memorial Health Care, Memorial campus - 119 Belmont Street - Jaquith 2.008, Worcester, MA 01605, USA. ⁹University of Rochester Medical Center, 601 Elmwood Ave, Box PSYCH, Rochester, NY 14642, USA. ¹⁰Allegheny Health Network, 4815 Liberty Avenue, Mellon Pavilion, Suite GR4, Pittsburgh, PA 15224, USA. ¹¹Butler Hospital and Brown University, 345 Blackstone Blvd, Providence, RI 02906, USA. ¹²University of Cape Town, Cape Town, South Africa.

Received: 10 July 2018 Accepted: 8 August 2018

Published online: 22 August 2018

References

- Proctor E, Luke D, Calhoun A, McMillen C, Brownson R, McCrary S, Padek M. Sustainability of evidence-based healthcare: research agenda, methodological advances, and infrastructure support. *Implement Sci*. 2015;10:88.
- O'Hara MW, Swain AM. Rates and risk of postpartum depression: a meta-analysis. *Int Rev Psychiatry*. 1996;8(1):37–54.
- Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. *Arch Womens Ment Health*. 2005;8:77–8.

4. Webb DA, Bloch JR, Coyne JC, et al. Postpartum physical symptoms in new mothers: their relationship to functional limitation and emotional wellbeing. *Birth*. 2008;35:179–87.
5. Postmontier B. Functional status outcomes in mothers with and without postpartum depression. *J Midwifery Womens Health*. 2008;53:310–8.
6. Gavin N, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. *Obstet Gynecol*. 2005;106:1071–83.
7. Sohr-Preston S, Scaramella L. Implications of timing of maternal depressive symptoms for early cognitive and language development. *Clin Child Fam Psychol Rev*. 2006;9:65–83.
8. Federenko IS, Wadhwa PD. Women's mental health during pregnancy influences fetal and infant developmental and health outcomes. *CNS Spectrums*. 2004;9: 198–206.
9. Murray L. The impact of postnatal depression on infant development. *J Child Psychol Psychiatr*. 1992;33:543–61.
10. Murray L, Cooper PJ. Postpartum depression and child development. *Psychol Med*. 1997;27(2):253–60.
11. Boury J, Larkin K, Krummel D. Factors related to postpartum depressive symptoms in low-income women. *Women Health*. 2004;39(3):19–34.
12. Price S, Proctor E. A rural perspective on perinatal depression: prevalence, correlates, and implications for help-seeking among low-income women. *J Rural Health*. 2009;25(2):158–66.
13. Hobfoll SE, Ritter C, Lavin J, Hulsizer MR, Cameron RP. Depression prevalence and incidence among inner-city pregnant and postpartum women. *J Consult Clin Psychol*. 1995;63(3):445–53.
14. Morris-Rush JK, Freda MC, Bernstein PS. Screening for postpartum depression in an inner-city population. *Am J Obstet Gynecol*. 2003; 188(5):1217–9.
15. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. *Brit Med J*. 2001;323:257–60.
16. Hobfoll SE, Ritter C, Lavin J, Hulsizer M, Cameron R. Depression prevalence and incidence among inner-city pregnant and postpartum women. *J Consult Clin Psychol*. 1995;63(3):445–53.
17. Scholle SH, Haskett RF, Hanusa BH, Pincus HA, Kupfer DJ. Addressing depression in obstetrics/gynecology practice. *Gen Hosp Psychiatry*. 2003; 25(2):83–90.
18. Davilla M, McFall SL, Cheng D. Acculturation and depressive symptoms among pregnant and postpartum Latinas. *Matern Child Health J*. 2008;13: 318–25.
19. Chaudron LH, Kitzman HJ, Peifer KL, Morrow S, Perez LM, Newman MC. Prevalence of maternal depressive symptoms in low-income Hispanic women. *J Clinical Psychiatry*. 2005;66(4):418–23.
20. Stein A, Malberg LE, Sylva K, Barnes J, Leach P, FCCC Team. The influence of maternal depression, caregiving, and socioeconomic status in the post-natal year on children's language development. *Child Care Health Dev*. 2008; 34(5):603–12.
21. Murray L, Fiori-Cowley A, Hooper R. The impact of postnatal depression and associated adversity on early mother-infant interactions and later infant outcome. *Child Dev*. 1996;67:2512–26.
22. Yonkers KA, Smith MV, Lin H, Howell HB, Shao L, Rosenheck RA. Depression screening of perinatal women: an evaluation of the healthy start depression initiative. *Psychiatr Serv*. 2009;60(3):322–8.
23. Venkatesh KK, Nadel H, Blewett D, Freeman MP, Kaimal AJ, Riley LE. Implementation of universal screening for depression during pregnancy: feasibility and impact on obstetric care. *Am J Obstet Gynecol*. 2016;215(4): 517.e511–8.
24. Morrell C, Sutcliffe P, Booth A, Stevens J, Scope A, Stevenson M, Harvey R, Bessey A, Cantrell A, Dennis C, Ren S, Ragonesi M, Barkham M, Churchill D, Henshaw C, Newstead J, Slade P, Spiby H, Stewart-Brown S. A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. *Health Technol Assess*. 2016;20(37):1–414.
25. Sidebottom AC, Hellerstedt WL, Harrison PA, Hennrikus D. An examination of prenatal and postpartum depressive symptoms among women served by urban community health centers. *Arch Womens Ment Health*. 2014;17(1): 27–40.
26. Beck C. Predictors of postpartum depression: an update. *Nurs Res*. 2001; 50(5):275–85.
27. Zlotnick C, Miller I, Pearlstein T, Howard M, Sweeney P. A preventive intervention for pregnant women on public assistance at the risk for postpartum depression. *Am J Psychiatry*. 2006;163(8):1443–5.
28. Zlotnick C, Tzilos G, Miller I, Seifer R, Stout R. Randomized controlled trial to prevent postpartum depression in mothers on public assistance. *J Affective Disorders*. 2016;189:263–8.
29. Zlotnick C, Johnson SL, Miller IW, Pearlstein T, Howard M. Postpartum depression in women receiving public assistance: pilot study of an interpersonal-therapy-oriented group intervention. *Am J Psychiatry*. 2001; 158(4):638–40.
30. Wiltsey-Stirman S, Kimberly J, Cook N, Calloway A, Castro F, Charns M. The sustainability of new programs and innovations: a review of the empirical literature and recommendations for future research. *Implement Sci*. 2012;7:17.
31. Scheirer M. Is sustainability possible? A review and commentary on empirical studies of program sustainability. *Am J Eval*. 2005;23:320–47.
32. Shediac-Rizkallah M, Bone LR. Planning for the sustainability of community-based health programs: conceptual frameworks and future directions for research, practice and policy. *Health Educ Res*. 1998;13(1):87–108.
33. Glasgow RE, Rhodes WJ. RE-AIM website: improving public health relevance and population health impact. 2016; <http://re-aim.org/>. Accessed 20 Dec 2016.
34. Proctor E, Luke D, Calhoun A, et al. Sustainability of evidence-based healthcare: research agenda, methodological advances, and infrastructure support. *Implement Sci*. 2015;10:88.
35. Kilbourne AM, Neumann MS, Pincus HA, Bauer MS, Stall R. Implementing evidence-based interventions in health care: application of the replicating effective programs framework. *Implement Sci*. 2007;2:42.
36. Kilbourne AM, Abraham KM, Goodrich DE, et al. Cluster randomized adaptive implementation trial comparing a standard versus enhanced implementation intervention to improve uptake of an effective re-engagement program for patients with serious mental illness. *Implement Sci*. 2013;8:136.
37. Cooper LA, Ford DE, Ghods BK, et al. A cluster randomized trial of standard quality improvement versus patient-centered interventions to enhance depression care for African Americans in the primary care setting: study protocol NCT00243425. *Implement Sci*. 2010;5:18.
38. Stamatakis KA, McQueen A, Filler C, et al. Measurement properties of a novel survey to assess stages of organizational readiness of evidence-based interventions in community chronic disease prevention settings. *Implement Sci*. 2012;65(7):1.
39. Phipps MG, Raker CA, Ware CF, Zlotnick C. Randomized controlled trial to prevent postpartum depression in adolescent mothers. *Am J Obstet Gynecol*. 2013;208(3):192.e191–6.
40. Crockett K, Zlotnick C, Davis M, Payne N, Washington R. A depression preventive intervention for rural low-income African-American pregnant women at risk for postpartum depression. *Arch Womens Ment Health*. 2008; 11(5–6):319–25.
41. Steckler A, Goodman RM, McLeroy KR, Davis S, Koch G. Measuring the diffusion of innovative health promotion programs. *Am J Health Promotion*. 1992;6(3):214–24.
42. Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation strategies: results from the expert recommendations for implementing change (ERIC) project. *Implement Sci*. 2015;10:21.
43. Moyers TB, Manuel JK, Wilson PG, Hendrickson SML, Talcott W, Durand P. A randomized trial investigating training in motivational interviewing for behavioral health providers. *Behav Cogn Psychother*. 2008;36:149–62.
44. Miller WR, Yahne CE, Moyers TB, Martinez J, Pirritano M. A randomized trial of methods to help clinicians learn motivational interviewing. *J Consult Clin Psychol*. 2004;72(6):1050–62.
45. Herschell A, Kolko DJ, Baumann BL, Davis AC. The role of therapist training in the implementation of psychosocial treatments: a review and critique with recommendations. *Clin Psychol Rev*. 2010;30(4):448–66.
46. Beidas RS, Kendall PC. Training therapists in evidence-based practice: a critical review of studies from a systems-contextual perspective. *Clin Psychol*. 2010;17(1):1–30.
47. Beidas RS, Maclean JC, Fishman J, et al. A randomized trial to identify accurate and cost-effective fidelity measurement methods for cognitive-behavioral therapy: project FACTS study protocol. *BMC Psychiatry*. 2016; 16(1):323.

48. Duffy SA, Cummins SE, Fellows JL, et al. Fidelity monitoring across the seven studies in the consortium of hospitals advancing research on tobacco (CHART). *Tob Induc Dis*. 2015;13(1):29.
49. McGrew JH, White LM, Stull LG, Wright-Berryman J. A comparison of self-reported and phone-based fidelity for assertive community treatment (ACT): a pilot study in Indiana. *Psychiatr Serv*. 2013;64(3):272–6.
50. Hanson RF, Chapman JE, Schoenwald SK, de Arellano M. Fidelity study of CII's delivery of trauma-focused cognitive behavioral therapy: Children's Institute, Inc.; 2016. www.mdr.org.
51. Keller MB, Lavori PW, Nielsen E. SCALUP (SCID-P plus SADS-L). Providence: Butler Hospital; 1987.
52. Warshaw MG, Keller MB, Stout R. Reliability and validity of the longitudinal interval follow-up evaluation for assessing outcome of anxiety disorders. *J Psychiatr Res*. 1994;28:531–45.
53. Argaw D, Fantahun M, Berhane Y. Factors affecting sustainability and success of community based reproductive health programmes in rural Northwest Ethiopia. In: Proceedings of the 13th Annual conference of the Ethiopian Public Health Association. Addis Ababa; 2002.
54. Ford JH 2nd, Krahn D, Wise M, Oliver KA. Measuring sustainability within the veterans administration mental health. *Qual Manag Health Care*. 2011;20(4):263–79.
55. Maher L, Gustafson D, Evans A. Sustainability model guide. NHS institute for innovation and improvement. 2007.
56. Beidas R, Aarons G, Barg F, Evans A, Hadley T, Hoagwood K, Marcus S, Schoenwald S, Walsh L, Mandell DS. Policy to implementation: evidence-based practice in community mental health - study protocol. *Implement Sci*. 2013;8:38.
57. Aarons G. Organizational climate for evidence-based practice implementation: development of a new scale. In: Proceedings of the Annual Association for Behavioral and Cognitive Therapies: November 2011. Toronto; 2011.
58. Office_of_Disease_Prevention_and_Health_Promotion. Maternal infant and child health - healthy people 2020 topics and objectives. 2016; <https://www.healthypeople.gov/2020/topics-objectives/topic/maternal-infant-and-child-health/objectives>. Accessed 9 Jan 2017.
59. National_Women's_Law_Center. Health care report card: making the grade on women's health: a national and state by state report card. Maternal mortality rate (per 100,000). 2016; <http://hrc.nwlc.org/status-indicators/maternal-mortality-rate-100000>. Accessed 9 Jan 2017.
60. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc, Series B*. 1995;57(1):289–300.
61. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. *Ann Stat*. 2001;29(4):1165–88.
62. Little R, Rubin M. Statistical analysis with missing data. New York: Wiley and Sons; 1987.
63. Hogan JW, Roy J, Korkontzelou C. Handling drop-out in longitudinal studies. *Stat Med*. 2004;23(9):1455–97.
64. Shen C, Weissfeld L. Application of pattern-mixture models to outcomes that are potentially missing not at random using pseudo maximum likelihood estimation. *Biostatistics*. 2005;6(2):333–47.
65. Preacher KJ, Selig JP. Advantages of Monte Carlo confidence intervals for indirect effects. *Commun Methods Meas*. 2012;6:77–98.
66. Biesanz JC, Falk CF, Savelei V. Assessing mediational models: testing and interval estimation for indirect effects. *Multivar Behav Res*. 2010;45:661–701.
67. Given CW, Given BA. Symptom management and psychosocial outcomes following cancer. In: Oeffinger K, editor. Submitted to seminars in oncology, special edition; 2013.
68. Bayliss EA, Ellis JL, Steiner JF. Seniors' self-reported multimorbidity captured biopsychosocial factors not incorporated into two other data-based morbidity measures. *J Clin Epidemiol*. 2009;62(5):550–7.
69. Robbins JM. Optimal structured nested models for the optimal sequential decisions. In: Lin DY, Heagerty PJ, editors. Proceedings of the second Seattle Wymposium on biostatistics. New York: Springer; 2004.
70. Moodie EE, Richardson TS, Stephens DA. Demystifying optimal dynamic treatment regimes. *Biometrics*. 2007;63(2):447–55.
71. Murphy SA. A generalization error for Q-learning. *J Mach Learn Res*. 2005;6:1073–97.
72. Sutton RS, Barto AG. Reinforcement learning: an introduction. Cambridge: MIT Press; 1998.
73. Murphy SA. Optimal dynamic treatment regimes (with discussions). *J R Stat Soc Ser B*. 2003;65:331–66.
74. Pluye P, Potvin L, Denis J, Pelletier J, Mannoni C. Program sustainability begins with the first events. *Eval Program Plann*. 2005;28:123–37.
75. Braun V, Clark V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3:77–101.
76. Cooper PJ, Murray L, Hooper R, West A. The development and validation of a predictive index for postpartum depression. *Psychol Med*. 1996;26:628–34.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

